β-连锁蛋白激活促进肝细胞癌免疫逃逸和对anti-PD-1治疗的耐药
研究利用新型基因工程小鼠肝细胞癌模型,探讨不同基因改变如何影响免疫监视和免疫治疗应答。在MYC;Trp53-/-肝细胞癌中表达外源性抗原可引发T细胞介导的免疫监视,肿瘤形成减少、生存期延长;部分抗原表达肿瘤通过上调β-连锁蛋白(CTNNB1)通路逃避免疫系统。β-连锁蛋白驱动的肿瘤对anti-PD-1耐药,可能作为肝细胞癌患者排除的生物标志物。
要点
- MYC;Trp53-/-肝细胞癌表达外源性抗原后出现T细胞免疫监视,肿瘤形成减少、生存期延长。
- β-连锁蛋白激活促进免疫逃逸,涉及树突状细胞募集缺陷和T细胞活性受损。
- β-连锁蛋白驱动的肿瘤对anti-PD-1耐药,可能作为肝细胞癌患者排除的生物标志物。
核心结论
- β-连锁蛋白激活促进免疫逃逸和对anti-PD-1治疗的耐药,可能作为肝细胞癌患者排除的新型生物标志物。
研究设计与样本
- 研究采用新型基因工程小鼠肝细胞癌模型,用于探究不同基因改变如何影响免疫监视和免疫治疗应答。
主要发现
- 在MYC;Trp53-/-肝细胞癌中表达外源性抗原引发T细胞介导的免疫监视,伴随肿瘤形成减少和生存期延长。
- 部分抗原表达的MYC;Trp53-/-肝细胞癌通过上调β-连锁蛋白(CTNNB1)通路逃避免疫系统。
- 在MYC;CTNNB1肝细胞癌中表达外源性抗原无效果,表明β-连锁蛋白促进免疫逃逸,涉及树突状细胞募集缺陷和T细胞活性受损。
- 在抗原表达的MYC;CTNNB1肝细胞癌中表达趋化因子CCL5可恢复免疫监视。
- β-连锁蛋白驱动的肿瘤对anti-PD-1耐药。
关键数值与推荐
- 在MYC;Trp53-/-肝细胞癌中表达外源性抗原导致T细胞介导的免疫监视,肿瘤形成减少和生存期延长。
- 在MYC;CTNNB1肝细胞癌中表达外源性抗原无效果。
- 在抗原表达的MYC;CTNNB1肝细胞癌中表达CCL5恢复免疫监视。
- β-连锁蛋白驱动的肿瘤对anti-PD-1耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PD-1 immune checkpoint inhibitors have produced encouraging results in patients with hepatocellular carcinoma (HCC). However, what determines resistance to anti-PD-1 therapies is unclear. We created a novel genetically engineered mouse model of HCC that enables interrogation of how different genetic alterations affect immune surveillance and response to immunotherapies. Expression of exogenous antigens in MYC;Trp53 -/- HCCs led to T cell-mediated immune surveillance, which was accompanied by decreased tumor formation and increased survival. Some antigen-expressing MYC;Trp53 -/- HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway. Accordingly, expression of exogenous antigens in MYC;CTNNB1 HCCs had no effect, demonstrating that β-catenin promoted immune escape, which involved defective recruitment of dendritic cells and consequently impaired T-cell activity. Expression of chemokine CCL5 in antigen-expressing MYC;CTNNB1 HCCs restored immune surveillance. Finally, β-catenin-driven tumors were resistant to anti-PD-1. In summary, β-catenin activation promotes immune escape and resistance to anti-PD-1 and could represent a novel biomarker for HCC patient exclusion. SIGNIFICANCE: Determinants of response to anti-PD-1 immunotherapies in HCC are poorly understood. Using a novel mouse model of HCC, we show that β-catenin activation promotes immune evasion and resistance to anti-PD-1 therapy and could potentially represent a novel biomarker for HCC patient exclusion.See related commentary by Berraondo et al., p. 1003.This article is highlighted in the In This Issue feature, p. 983.
引用
- Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, et al. β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov. 2019. PMID: 31186238. doi:10.1158/2159-8290.CD-19-0074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。